Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...
Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $15.34 million during the quarter, compared to analyst estimates of $16.33 million.
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...